-
ESMO–EHA Release Joint Clinical Practice Guidelines for Peripheral T-Cell Lymphoma, Defining a New Standard in Diagnosis and Treatment丨EHA 2025
Development and Core Framework of the New Guidelines: A Decade of Refinement At the beginning of the meeting, Professor Massimo Federico reviewed the developmental history of PTCL guidelines. He noted…
-
Redefining “Stem Cell”: Professor Sten Eirik Jacobsen Unveils New Mechanisms of Lineage Restriction in Hematopoietic Stem Cells丨EHA 2025
The human hematopoietic system is responsible for vital functions of substance transport and immune defense, with an astonishing cell turnover rate—approximately 90% of all cells are replaced daily by the…
-
Professor Johanna Olweus on Cutting-Edge Breakthroughs and Clinical Translation of TCR-T Therapy | EHA 2025
As a star in the current immunotherapy landscape, Chimeric Antigen Receptor T-Cell (CAR-T) therapy has achieved tremendous success in some hematological tumors. However, its limitations are becoming increasingly apparent. “Currently…
-
Innovative Unsupervised Learning Reshapes AML Subtyping: HARMONY Alliance Study Reveals 17 Novel Biological Subgroups丨EHA 2025
Acute Myeloid Leukemia (AML), as a highly heterogeneous malignancy, presents immense challenges to precise clinical subtyping and treatment due to its complex biological characteristics. Although existing clinical guidelines, such as…
-
From Biological Mechanisms to Targeted Therapy: The Treatment of Immune Thrombocytopenia (ITP) Enters an Era of Precision丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on “Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy.” She systematically…
-
EHA Releases Landmark Guidelines, Reshaping the Treatment Landscape for Aggressive Large B-cell Lymphoma丨EHA 2025
Precision Diagnosis and Risk Stratification: The Cornerstone of Individualized Treatment The new EHA guidelines first emphasize the central role of precise diagnosis and comprehensive risk assessment in the management of…
-
Overcoming Venetoclax Resistance in CLL: A Novel BCL2/BCL-xL Dual-Efficacy Degrader Reshapes the Therapeutic Landscape丨EHA 2025
In the high summer of 2025, the highly anticipated European Hematology Association (EHA) Annual Meeting was convened, bringing together top global experts in hematologic oncology to discuss cutting-edge progress and future directions in the field. In the Chronic Lymphocytic Leukemia (CLL) session, Dr. Daisy Diaz, a postdoctoral fellow from MD Anderson Cancer Center in the…
-
EHA 2025: Professor Alberto Orfao on Immune Mechanisms and Diagnostic Breakthroughs in Rare Diseases
As a scholar with a research career spanning over 30 years, Professor Alberto Orfao began his lecture by expressing his profound gratitude. He attributed this honor to the hundreds of…
Connecting Medical Expertise through Media